摘要：11 月 24 日，默沙东合作伙伴科伦博泰宣布，其 TROP2 靶向 ADC 药物 sacituzumab tirumotecan（sac-TMT）联合 Keytruda（帕博利珠单抗），在一线 PD-L1 阳性非小细胞肺癌（NSCLC）III 期试验中获胜。该试验（OptiTROP-Lung05）显示，联合疗法较 Keytruda 单药显著改善患者无进展生存期（PFS），科伦博泰计划据此向...
Source Link摘要：11 月 24 日，默沙东合作伙伴科伦博泰宣布，其 TROP2 靶向 ADC 药物 sacituzumab tirumotecan（sac-TMT）联合 Keytruda（帕博利珠单抗），在一线 PD-L1 阳性非小细胞肺癌（NSCLC）III 期试验中获胜。该试验（OptiTROP-Lung05）显示，联合疗法较 Keytruda 单药显著改善患者无进展生存期（PFS），科伦博泰计划据此向...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.